文献速递系统性红斑狼疮类风湿关节炎

开发用于监测体内给予糖皮质激素所介导药效学反应的分子特征

Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids.
PubMed 文献 · Arthritis Rheumatol · 2018-07-12

研究基于健康志愿者外周血单核细胞体外实验,鉴定泼尼松龙调节的基因并构建复合评分,在口服泼尼松龙后表达呈剂量依赖性升高、4小时达峰、48小时回落;在系统性红斑狼疮和类风湿关节炎队列中,该特征表达与淋巴细胞百分比负相关、与中性粒细胞计数正相关,且大体与 reported 糖皮质激素使用一致,但剂量队列内患者间变异显著。

要点

  • 糖皮质激素基因特征在口服泼尼松龙后呈剂量依赖性升高,4小时达峰,48小时回落至基线。
  • 部分糖皮质激素受体激动剂后该特征表达较低,与其转录激活潜力降低一致。
  • 在系统性红斑狼疮和类风湿关节炎患者中,该特征与淋巴细胞百分比负相关、与中性粒细胞计数正相关。

核心结论

  • 本研究鉴定的糖皮质激素基因特征可作为糖皮质激素暴露的药效学标志物。

研究设计与样本

  • 从健康志愿者外周血单核细胞体外实验中鉴定泼尼松龙调节的基因。
  • 采用相对于载体对照变化大于2倍且校正P值小于0.05的标准,鉴定出64个上调基因和18个下调基因。
  • 使用单样本基因集富集分析算法生成上调基因的复合评分。

主要发现

  • 健康志愿者口服泼尼松龙后,外周血白细胞中糖皮质激素基因特征表达显著升高。
  • 该特征表达呈剂量依赖性升高,给药后4小时达峰,给药后48小时回落至基线水平。
  • 接受部分糖皮质激素受体激动剂的健康志愿者中该特征表达较低,与该化合物转录激活潜力降低一致。
  • 在系统性红斑狼疮和类风湿关节炎患者队列中,该特征表达与外周血淋巴细胞百分比负相关,与外周血中性粒细胞计数正相关。
  • 该特征表达大体与这些人群中报告的糖皮质激素使用一致,但剂量队列内患者间变异显著。

关键数值与推荐

  • 体外鉴定标准:相对于载体对照变化大于2倍且校正P值小于0.05,鉴定出64个上调基因和18个下调基因。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 剂量队列内患者间变异显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop an objective, readily measurable pharmacodynamic biomarker of glucocorticoid (GC) activity. METHODS: Genes modulated by prednisolone were identified from in vitro studies using peripheral blood mononuclear cells from normal healthy volunteers. Using the criteria of a >2-fold change relative to vehicle controls and an adjusted P value cutoff of less than 0.05, 64 up-regulated and 18 down-regulated genes were identified. A composite score of the up-regulated genes was generated using a single-sample gene set enrichment analysis algorithm. RESULTS: GC gene signature expression was significantly elevated in peripheral blood leukocytes from normal healthy volunteers following oral administration of prednisolone. Expression of the signature increased in a dose-dependent manner, peaked at 4 hours postadministration, and returned to baseline levels by 48 hours after dosing. Lower expression was detected in normal healthy volunteers who received a partial GC receptor agonist, which is consistent with the reduced transactivation potential of this compound. In cohorts of patients with systemic lupus erythematosus and patients with rheumatoid arthritis, expression of the GC signature was negatively correlated with the percentages of peripheral blood lymphocytes and positively correlated with peripheral blood neutrophil counts, which is consistent with the known biology of the GC receptor. Expression of the signature largely agreed with reported GC use in these populations, although there was significant interpatient variability within the dose cohorts. CONCLUSION: The GC gene signature identified in this study represents a pharmacodynamic marker of GC exposure.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Hu Y, Carman JA, Holloway D, et al. Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids. Arthritis Rheumatol. 2018. PMID: 29534336. doi:10.1002/art.40476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。